{"id":239775,"date":"2026-06-27T03:16:01","date_gmt":"2026-06-27T08:16:01","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/06\/combination-of-neuronavigation-guided-focused-ultrasound-neurosurgery"},"modified":"2026-06-27T03:16:01","modified_gmt":"2026-06-27T08:16:01","slug":"combination-of-neuronavigation-guided-focused-ultrasound-neurosurgery","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/06\/combination-of-neuronavigation-guided-focused-ultrasound-neurosurgery","title":{"rendered":"Combination of Neuronavigation-Guided Focused Ultrasound\u2026 : Neurosurgery"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/combination-of-neuronavigation-guided-focused-ultrasound-neurosurgery2.jpg\"><\/a><\/p>\n<p>This was a prospective, single-arm, open-label pilot trial. The primary end point was 6-month progression-free survival (PFS). Disease progression was assessed according to the Response Assessment in Neuro-Oncology criteria by independent radiological review. Radiological response was evaluated using fluid-attenuated inversion-recovery sequences to compare FUS-exposed vs nonexposed regions. Plasma cell\u2013free DNA (cfDNA) concentrations were measured before and after FUS treatment.<\/p>\n<p>RESULTS:<\/p>\n<p>Between July 2020 and August 2023, 6 patients received a median of 14.5 sessions of biweekly FUS-BEV (10 mg\/kg). The median PFS was 11 months, with a 6-month PFS rate of 66.7%. The only FUS-related adverse event was transient scalp heating (grade 1; 1.9%). A fluid-attenuated inversion recovery normalization effect emerged within 1 month after treatment. Plasma cfDNA increased significantly post-FUS, with total cfDNA rising 2.03 \u00b1 0.76-fold, <em >EGFR<\/em> cfDNA 1.77 \u00b1 0.76-fold, and <em >HMBS<\/em> cfDNA 1.68 \u00b1 0.66-fold.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This was a prospective, single-arm, open-label pilot trial. The primary end point was 6-month progression-free survival (PFS). Disease progression was assessed according to the Response Assessment in Neuro-Oncology criteria by independent radiological review. Radiological response was evaluated using fluid-attenuated inversion-recovery sequences to compare FUS-exposed vs nonexposed regions. Plasma cell\u2013free DNA (cfDNA) concentrations were measured before [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-239775","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=239775"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239775\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=239775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=239775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=239775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}